How much is Wegovy in Canada?
A Wegovy (semaglutide) pen costs $388.64 at every dose, the maker’s price submitted to Canada’s Drug Agency, and each pen holds 4 weekly doses. That is about $5,052 a year. No province covers Wegovy for weight, so without private insurance you pay the pharmacy’s price, which adds its markup and fees.
- Every GLP‑1 medicine is a prescription drug in Canada. A doctor, nurse practitioner or other authorized prescriber must assess you first.1
- Prices here are official or maker-submitted prices, with the date we checked them. We never quote a pharmacy’s, clinic’s or savings card’s price, and we don’t name or rank sellers.
- Canadian law bans advertising any drug to the general public as a treatment, preventative or cure for obesity or diabetes.2 This page is information, not an ad, and nothing here is for sale. The risks are in Guide 5: Side effects and risks.
What is the official price of a Wegovy pen?
Canada’s Drug Agency used Novo Nordisk’s submitted price of $388.64 per pen, “regardless of strength”, from 0.25 mg to 2.4 mg.3
Each FlexTouch pen holds 4 weekly doses, so it lasts 4 weeks.3 A year is 52 doses, or 13 pens: about $5,052, or $421 a month, by our arithmetic. The agency’s own yearly figure is $5,066, because it counts 365 days.3
Ontario’s formulary lists Wegovy as “Off-Formulary Interchangeable”, with no price.4 Pharmacies set their own cash prices and fees, so the counter price can differ.
Official Canadian prices, dose by dose. Free, no sign-up.
Is there a generic Wegovy?
Not yet in pharmacies. Sevmia, the first generic of Wegovy, was approved on 29 June 2026, but Health Canada’s database still showed it as not marketed on 14 October 2026.1
Sevmia comes only as a pen that gives 1 mg doses; its monograph says other products are needed for every other dose.5 Ontario lists it at $325.048 a pen, as an off-formulary product.4 Ozempic and its generics are approved for type 2 diabetes, not weight management.6 More in What is Sevmia?
Does insurance pay for Wegovy?
No province covers Wegovy. BC listed it as a non-benefit in December 2025, after Novo Nordisk said it would no longer seek public coverage in Canada.7
Some private plans cover it, often with BMI rules and forms: see private insurance and GLP‑1s. What you pay yourself may count toward the Medical Expense Tax Credit: see Are GLP‑1s tax deductible in Canada? Plan-by-plan detail is in Guide 6.
- Stomach effects are very common. In Canada’s Wegovy monograph, 44 in 100 people on 2.4 mg felt sick (nausea), against 16 in 100 on a dummy injection.8
- Gallstones are common (up to 1 in 10) and pancreatitis uncommon (up to 1 in 100) on the EU Wegovy label.9
- Who shouldn’t take it. Not for anyone with a personal or family history of medullary thyroid cancer or MEN 2. Stop at least 2 months before a planned pregnancy.8
Read the full picture
Related questions
Sources
- Health Canada. Drug Product Database: product records, schedule, route and status for every semaglutide, tirzepatide, liraglutide and dulaglutide product (all on the “Prescription” schedule; all subcutaneous injections or oral tablets; for example Sevmia “Approved”, not marketed; first generic semaglutide marketed 6 May 2026). Searched 14 October 2026. Link
- Food and Drugs Act (R.S.C., 1985, c. F-27), section 3(1): “No person shall advertise any food, drug, cosmetic or device to the general public as a treatment, preventative or cure for any of the diseases … referred to in Schedule A.1”; Schedule A.1 lists diabetes and obesity. Justice Laws Website. Checked 14 October 2026. Link
- Canada’s Drug Agency (CDA-AMC). Semaglutide (Wegovy) SR0841, pharmacoeconomic review: submitted price “$388.64 per multiuse, prefilled, single-dose pen, regardless of strength … each pen contains 4 doses”; annual cost of Wegovy $5,066, of Ozempic for type 2 diabetes $2,844 to $5,688. 2025. Link
- Ontario Ministry of Health. Ontario Drug Benefit Formulary search (Ozempic $227.94 a pen, with the plan paying $78.141; Apo-Semaglutide and Dr. Reddy’s semaglutide $78.141 a pen; Sevmia $325.048 a pen and Wegovy with no price, both “Off-Formulary Interchangeable”; Rybelsus $7.5303 a tablet at every strength; no tirzepatide). Checked 14 October 2026. Link
- Apotex Inc. Sevmia (semaglutide injection) Product Monograph, date of authorization 29 June 2026 (“Multi-use pre-filled pen delivering doses of 1 mg”, 4 mg per pen; “SEVMIA can be prescribed only for 1 mg once weekly dosing. Alternative products are needed to achieve doses … exclusive of the 1 mg dose”). PDF
- Novo Nordisk Canada. Ozempic (semaglutide injection) Product Monograph, 13 July 2026 (type 2 diabetes indications, including reducing the risk of major heart and blood-vessel events in adults with type 2 diabetes and heart or chronic kidney disease, and of kidney decline in type 2 diabetes with chronic kidney disease; GLP‑1 receptor agonist; 0.25 mg for 4 weeks, then 0.5 mg, then 1 mg and 2 mg if needed, maximum 2 mg; SUSTAIN 2 and SUSTAIN 9 results; Table 2 adverse reactions: nausea 17.0% on 0.5 mg and 19.9% on 1 mg vs 6.3% on comparators; once weekly “at any time of the day, with or without meals”; missed dose within 5 days; stop at least 2 months before a planned pregnancy; perioperative aspiration warning). PDF
- BC PharmaCare. Drug coverage decision: semaglutide (Wegovy), “Non-benefit”, 18 December 2025 (the pan-Canadian Pharmaceutical Alliance concluded negotiations without agreement on 1 December 2025; Novo Nordisk “would no longer be seeking public coverage of Wegovy in Canada”). PDF
- Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, 2 October 2026 (indications; dose escalation 0.25, 0.5, 1, 1.7 mg every 4 weeks to 2.4 mg; reassess after 12 weeks on the maintenance dose; STEP 1–3 results; Table 4: nausea 44% vs 16% on placebo; perioperative aspiration warning). PDF
- European Medicines Agency. Wegovy: EPAR product information (package leaflet section 4: nausea, vomiting, diarrhea, constipation and stomach pain “very common (may affect more than 1 in 10 people)”; gallstones “common”; acute pancreatitis “uncommon”). PDF
Last checked 14 Oct 2026 · Next review due 14 Apr 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on 14 Oct 2026. Prices are official or maker-submitted prices, never a seller’s, savings-card or coupon price, and we don’t name or rank sellers. Figures marked as our arithmetic are worked out from those sources. It’s general information, not medical advice, and not an advertisement for any medicine. Talk to a doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. How we write